• Home
  •  / Five Prime Therapeutics

Five Prime Therapeutics

OverviewSuggest Edit

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics to improve the lives of patients with serious diseases. The Company currently has three product candidates in clinical development covering multiple potential indications. Cabiralizumab (FPA008) is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis and in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that we are initially developing to treat patients with gastric (stomach) cancer and is in a Phase 1 clinical trial. FP-1039 is a fusion protein that “traps” and neutralizes cancer-promoting fibroblast growth factors, or FGFs, involved in cancer cell proliferation and new blood vessel formation that is in Phase 1b clinical development to treat patients with malignant pleural mesothelioma.

TypePublic
Founded2001
HQSouth San Francisco, CA, USMap
Websitefiveprime.com
Employee Ratings3More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)87(-48%)
Revenue (FY, 2020)$13.2 M(-11%)
Share Price (Apr 2021)$38
Cybersecurity ratingBMore

Key People/Management at Five Prime Therapeutics

William R. Ringo

William R. Ringo

Chairman of the Board
Thomas Civik

Thomas Civik

President and Chief Executive Officer, Director
Francis Sarena

Francis Sarena

Chief Strategy Officer and Secretary
Peder K. Jensen

Peder K. Jensen

Director
Franklin M. Berger

Franklin M. Berger

Board Member
Helen Collins

Helen Collins

Senior Vice President and Chief Medical Officer
Show more

Five Prime Therapeutics Office Locations

Five Prime Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
111 Oyster Point Blvd
Show all (1)

Five Prime Therapeutics Financials and Metrics

Five Prime Therapeutics Revenue

Five Prime Therapeutics's revenue was reported to be $13.18 m in FY, 2020
USD

Revenue (FY, 2020)

13.2m

Net income (FY, 2020)

(84.3m)

EBIT (FY, 2020)

(92.9m)

Market capitalization (22-Apr-2021)

1.8b

Closing stock price (22-Apr-2021)

38.0

Cash (31-Dec-2020)

69.4m

EV

1.7b
Five Prime Therapeutics's current market capitalization is $1.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

49.9m14.9m13.2m

General and administrative expense

10.4m13.6m22.6m35.8m40.0m39.7m42.7m40.6m

R&D expense

32.8m43.2m70.2m94.1m150.9m156.4m114.1m65.5m

Operating expense total

43.2m56.8m92.8m129.9m190.9m196.0m156.8m106.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

32.5m7.6m5.8m5.3m3.3m3.0m8.4m3.4m2.0m

General and administrative expense

2.6m3.3m3.0m3.4m4.2m4.6m5.2m8.6m8.1m9.1m10.5m9.4m9.7m10.5m9.8m9.8m10.5m9.7m13.2m10.5m8.0m13.7m

R&D expense

8.2m8.9m11.9m9.8m11.2m13.3m24.7m18.3m22.2m23.9m33.8m41.7m42.7m43.6m33.4m44.7m31.8m29.4m26.9m18.6m12.6m21.4m

Operating expense total

10.8m12.2m14.9m13.2m15.4m17.9m29.9m26.9m30.3m33.0m44.2m51.1m52.4m54.0m43.2m54.5m42.3m39.1m40.2m29.0m20.6m35.2m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

8.2m15.3m150.0m7.7m59.8m44.0m55.8m69.4m

Accounts Receivable

296.0k410.0k4.1m13.1m5.1m4.1m85.0k

Prepaid Expenses

1.6m1.8m6.8m5.4m13.3m6.2m5.1m

Inventories

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

77.6m11.7m13.1m13.1m14.5m19.1m37.0m133.0m38.2m56.4m47.2m59.7m36.4m65.9m52.8m64.0m29.6m38.3m48.9m67.7m58.7m36.0m

Accounts Receivable

383.0k20.1m177.0k91.0k133.0k718.0k1.7m1.8m3.4m2.3m5.9m3.8m4.4m4.3m2.7m5.0m3.4m2.6m3.7m2.2m2.2m1.5m

Prepaid Expenses

866.0k1.2m1.3m1.8m3.1m2.6m5.5m6.0m6.0m7.8m8.3m8.8m8.2m9.3m7.5m6.2m10.2m13.3m7.8m3.8m5.2m3.8m

Current Assets

87.9m150.2m142.0m131.8m220.3m210.7m190.5m490.6m480.1m454.0m399.2m363.3m333.4m403.0m363.0m332.9m250.5m230.0m197.5m150.3m134.5m123.3m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(28.9m)(37.4m)249.6m(65.7m)(150.2m)(140.4m)(137.2m)(84.3m)

Depreciation and Amortization

1.7m1.6m1.7m1.7m2.5m5.0m3.2m

Accounts Payable

(209.0k)701.0k798.0k(1.6m)1.9m(265.0k)(72.0k)(685.0k)

Cash From Operating Activities

(25.3m)15.3m289.1m(79.8m)(112.2m)(122.5m)(113.9m)(64.7m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(21.6m)(8.6m)(18.5m)(25.6m)(11.0m)(22.5m)(46.5m)(13.0m)(26.2m)(45.6m)(33.4m)(77.7m)(121.0m)(20.4m)(54.4m)(101.7m)(35.4m)(69.8m)(105.8m)(20.1m)(37.1m)(63.5m)

Depreciation and Amortization

1.3m391.0k772.0k1.2m400.0k823.0k1.3m375.0k782.0k1.2m515.0k1.1m1.7m1.2m2.5m3.7m1.3m2.7m3.9m1.3m2.0m2.7m

Accounts Payable

467.0k(1.0k)419.0k324.0k(192.0k)257.0k469.0k(874.0k)(1.2m)(1.4m)473.0k987.0k2.6m(406.0k)229.0k258.0k3.2m2.3m3.0m(388.0k)(809.0k)(759.0k)

Cash From Operating Activities

(15.7m)(5.6m)6.5m(3.4m)(10.6m)(20.2m)(44.5m)(34.1m)(49.2m)(64.8m)(27.9m)(57.0m)(84.7m)(10.6m)(39.0m)(69.9m)(32.7m)(56.3m)(84.2m)(15.1m)(36.1m)(51.4m)
show all
USDQ3, 2013

Financial Leverage

1.4 x
Show all financial metrics

Five Prime Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

Learn more about our premium products
SecurityScorecard logo

Five Prime Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Five Prime Therapeutics Online and Social Media Presence

Five Prime Therapeutics's Trends

Embed Graph

Five Prime Therapeutics News and Updates

March 04, 2021

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Five Prime Therapeutics, Inc. Buyout

WILMINGTON, Del., March 04, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Five Prime Therapeutics, Inc. (“Five Prime”) (NASDAQ GS: FPRX) regarding possible breaches of fiduciary duties and other violations of law related to Five Prime’s agreement to be acquired by…
January 05, 2021

Thinking about buying stock in Zomedica, Zosano Pharma, TapImmune, Five Prime Therapeutics, or Inuvo?

NEW YORK, Jan. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, ZSAN, MRKR, FPRX, and INUV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
May 12, 2018

Five Prime Therapeutics' (FPRX) CEO Aron Knickerbocker on Q1 2018 Results - Earnings Call Transcript

Five Prime Therapeutics Blogs

March 09, 2021

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call Content Import Tue, 03/09/2021 - 17:00 Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call March 9, 2021 at 5:00 PM EST This release is a …
March 04, 2021

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Bemarituzumab is a Strong Strategic Fit With Amgen’s Innovative Oncology Portfolio Amgen to Host Investor Call at 10:30 a.m.
March 02, 2021

Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 2, 2021-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday, March 10, 2021 after the U.S. financial markets close.
February 26, 2021

Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 26, 2021-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik , President and Chief Executive Officer, and Helen Collins , M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside
February 22, 2021

Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 22, 2021-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik , President and Chief Executive Officer, and Helen Collins , M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside
February 05, 2021

Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day

Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day Content Import Fri, 02/05/2021 - 09:25 Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day February 5, 2021 at 9:25 AM EST This releas…
Show more

 Five Prime Therapeutics Frequently Asked Questions

  • When was Five Prime Therapeutics founded?

    Five Prime Therapeutics was founded in 2001.

  • Who are Five Prime Therapeutics key executives?

    Five Prime Therapeutics's key executives are William R. Ringo, Thomas Civik and Francis Sarena.

  • How many employees does Five Prime Therapeutics have?

    Five Prime Therapeutics has 87 employees.

  • What is Five Prime Therapeutics revenue?

    Latest Five Prime Therapeutics annual revenue is $13.2 m.

  • What is Five Prime Therapeutics revenue per employee?

    Latest Five Prime Therapeutics revenue per employee is $151.5 k.

  • Who are Five Prime Therapeutics competitors?

    Competitors of Five Prime Therapeutics include Pharming Group, Effector Therapeutics and Heat Biologics.

  • Where is Five Prime Therapeutics headquarters?

    Five Prime Therapeutics headquarters is located at 111 Oyster Point Blvd, South San Francisco.

  • Where are Five Prime Therapeutics offices?

    Five Prime Therapeutics has an office in South San Francisco.

  • How many offices does Five Prime Therapeutics have?

    Five Prime Therapeutics has 1 office.